SecBot SecBot
8-K ·Filed Jun 22, 2026

DYN

Dyne Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001818794-26-000005
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine board addition with no strategic or operational signal. The option grant represents modest dilution (~57K shares vs ~80M+ outstanding). No immediate trading catalyst, monitor for any future committee assignments or strategic moves.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$20.26
T+0 close · Jun 22, 2026 · via day close
Latest settled
−14.59%
T+60 · $17.31
Vs SPY
−17.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 23 $20.26entry
  2. T+1 · 5mo ago +0.35%α +0.39% · $20.33
  3. T+5 · 5mo ago +4.94%α +3.92% · $21.26
  4. T+20 · 4mo ago +15.75%α +14.59% · $23.45
  5. T+60 · 2mo ago −14.59%α −17.38% · $17.31
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dyne Therapeutics elected Barry E. Greene as an independent Class I director to its board. This is a routine board appointment with standard compensation under the non-employee director program, no material financial or strategic impact.

Key Facts

  • Barry E. Greene elected as Class I director effective June 22, 2026
  • Not appointed to any board committees
  • Received option to purchase 57,463 shares at $20.87 per share, vesting over 3 years
  • Annual cash compensation of $45,000 as board member
  • No family relationships or transactions with existing directors/officers

Financial Impact

Standard non-employee director compensation, option grant valued at ~$1.2M at grant price, annual cash retainer $45,000

dilutioncompensation

Risk Factors

  • No material risk, standard director appointment

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001818794-26-000005
Document: 0001818794-26-000005-index-headers.html0001818794-26-000005
Document: 0001818794-26-000005-index.html0001818794-26-000005
Document: 0001818794-26-000005.txt0001818794-26-000005

Track record

54 reports on DYN

Performance horizon

12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
  7. Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
  8. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
  9. Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
  10. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
Showing 10 of 54

US Market Status

Market Closed · Opens Wed (10h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 22, 2026